Stylized human lung with glowing circuitry representing immunotherapy and SABR.

Immunotherapy vs. SABR: Which Treatment Strategy Holds the Key for Early-Stage NSCLC?

Avery Sinclair in Health & Wellness December 2025 • 4 min read.

"A Randomized Trial Comparing Immunotherapy Plus SABR (I-SABR) Versus SABR Alone Sheds Light on the Future of Early-Stage Non-Small Cell Lung Cancer Treatment"

Lung cancer remains a significant global health challenge, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. Early-stage NSCLC offers the best chance for curative treatment, but recurrence remains a major concern. Stereotactic ablative radiotherapy (SABR) has emerged as a highly effective local treatment for early-stage NSCLC, delivering high doses of radiation to precisely target tumors.

However, SABR's benefits are primarily local, and it may not address the risk of distant metastases. Immunotherapy, on the other hand, harnesses the power of the body's own immune system to fight cancer cells throughout the body. The combination of SABR and immunotherapy, known as I-SABR, has the potential to provide both local and systemic control of NSCLC, potentially improving outcomes for patients with early-stage disease.

A recent randomized phase II trial (NCT03110978) has investigated the efficacy of I-SABR compared to SABR alone in patients with early-stage NSCLC. This article delves into the design and findings of this trial, exploring the potential benefits and challenges of combining immunotherapy with SABR in the treatment of early-stage NSCLC. We'll also look at what this could mean for the future of cancer treatment.

Decoding the I-SABR Trial: Combining Local Precision with Systemic Immunity

Stylized human lung with glowing circuitry representing immunotherapy and SABR.

The randomized phase II trial (NCT03110978) was designed to evaluate the effectiveness of SABR with or without concurrent and adjuvant nivolumab in patients with early-stage or isolated recurrent NSCLC. Nivolumab, an immune checkpoint inhibitor, blocks the PD-1 protein on immune cells, unleashing their ability to attack cancer cells.

The trial included patients with:

Stage I disease (tumor size ≤5 cm, N0M0)
Selected cases of stage IIa disease (tumor size >5 cm but ≤7 cm, N0M0)
Isolated lung-parenchymal recurrent or persistent NSCLC suitable for SABR

Patients were randomized to receive either SABR alone or I-SABR. The I-SABR regimen consisted of SABR (biological effective dose >100 Gy) plus nivolumab for a total of 7 doses. Researchers collected tumor tissue, blood, and stool samples before, during, and after treatment to analyze biomarkers and immune responses.

The Future of Early-Stage NSCLC Treatment: A Personalized Approach

The I-SABR trial represents a significant step forward in the treatment of early-stage NSCLC. By combining the local precision of SABR with the systemic effects of immunotherapy, I-SABR holds the promise of improving outcomes for patients with this challenging disease. Further research is needed to identify the patients who are most likely to benefit from I-SABR and to optimize the treatment regimen. As we continue to unravel the complexities of the immune system and its interaction with cancer, we are moving closer to a future where cancer treatment is tailored to the individual characteristics of each patient.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What is SABR, and why is it used in the treatment of early-stage NSCLC?

SABR, or Stereotactic ablative radiotherapy, is a highly precise form of radiation therapy that delivers high doses of radiation to a tumor, targeting it directly. Its significance in early-stage NSCLC treatment lies in its ability to effectively control the cancer locally. However, SABR's primary limitation is its local effect, meaning it may not address cancer cells that have spread to other parts of the body, increasing the risk of distant metastases. This is why researchers are investigating combination treatments like I-SABR.

What is I-SABR, and how does it work in treating early-stage NSCLC?

I-SABR is the combination of Stereotactic ablative radiotherapy (SABR) and immunotherapy. In the context of early-stage NSCLC, I-SABR aims to combine the local precision of SABR with the systemic effects of immunotherapy. Immunotherapy, specifically nivolumab in this trial, works by harnessing the body's immune system to fight cancer cells throughout the body, potentially addressing the risk of distant metastases that SABR alone might not. The implication of I-SABR is a potential improvement in outcomes for patients, offering both local control through SABR and systemic control through immunotherapy.

What is the role of nivolumab in the I-SABR treatment?

Nivolumab is an immune checkpoint inhibitor used in the I-SABR trial. It functions by blocking the PD-1 protein on immune cells, effectively unleashing these cells to attack and eliminate cancer cells. Its importance in the treatment strategy lies in its ability to provide systemic control of the cancer, complementing the local effect of SABR. By activating the immune system, nivolumab can potentially target cancer cells throughout the body, including those that have spread beyond the primary tumor site, addressing the limitations of SABR alone. This offers the potential for a more comprehensive cancer treatment.

Why is early-stage NSCLC important in the context of this research?

Early-stage NSCLC refers to the initial phases of Non-Small Cell Lung Cancer, offering the best chance for a cure. However, even at this stage, recurrence remains a significant concern. The significance of early-stage NSCLC in this trial lies in the focus on patients with the best prognosis, which is ideal for testing combination treatment strategies such as I-SABR. The implication is that, if successful, these treatments could significantly improve the long-term outcomes and survival rates for patients with early-stage disease. The trial explores the potential to improve these outcomes with novel treatment combinations.

What was the design of the randomized phase II trial (NCT03110978) comparing I-SABR and SABR alone?

The randomized phase II trial (NCT03110978) compared I-SABR (Stereotactic ablative radiotherapy plus immunotherapy) to SABR alone for early-stage NSCLC. The trial included patients with Stage I disease (tumor size ≤5 cm, N0M0), select cases of stage IIa disease (tumor size >5 cm but ≤7 cm, N0M0), and those with isolated lung-parenchymal recurrent or persistent NSCLC suitable for SABR. This trial design allows for a direct comparison of the effectiveness of the two treatment approaches, investigating whether the addition of immunotherapy with nivolumab improves outcomes compared to SABR alone. The main goal of the trial is to see if the combination of I-SABR improves the results for lung cancer patients.